v3.26.3
Note 2 - Significant Accounting Policies - Segment Information (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Cost of sales $ 15,198 $ 12,173 $ 38,097 $ 35,030
Research and development 18,283 15,912 56,973 45,227
Stock-based compensation     5,870 5,327
Total operating costs and expenses 49,782 44,902 147,341 132,725
Operating Segments [Member] | Development and Commercialization of Innovative Products to Enhance Cancer Care [Member]        
Cost of sales 15,198 12,173 38,097 35,030
General and administrative 5,217 6,142 16,706 18,860
Commercialization 9,795 9,623 31,957 30,330
Operating costs and expenses 47,761 43,229 141,471 127,398
Stock-based compensation 2,021 1,673 5,870 5,327
Total operating costs and expenses 49,782 44,902 147,341 132,725
Operating Segments [Member] | Development and Commercialization of Innovative Products to Enhance Cancer Care [Member] | Clinical Research [Member]        
Research and development 9,341 7,789 31,449 21,881
Operating Segments [Member] | Development and Commercialization of Innovative Products to Enhance Cancer Care [Member] | Medical Affairs [Member]        
Research and development 1,203 1,323 3,683 4,107
Operating Segments [Member] | Development and Commercialization of Innovative Products to Enhance Cancer Care [Member] | Other Research and Development [Member]        
Research and development [1] $ 7,007 $ 6,179 $ 19,579 $ 17,190
[1] Other research and development expense includes regulatory affairs, pharmacovigilance, quality assurance, chemical manufacturing and other costs.